# Omission of Surgery in Clinically Low-risk HER2positive Breast Cancer With High HER2 Addiction and a Complete Response Following Standard Anti-HER2-based Neoadjuvant Therapy

> **NCT04578106** · PHASE2 · TERMINATED · sponsor: **Fundacio Clinic Barcelona** · enrollment: 5 (actual)

## Conditions studied

- HER2-positive Breast Cancer
- Stage I Breast Cancer

## Interventions

- **BIOLOGICAL:** Trastuzumab and pertuzumab Subcutaneous Fixed-Dose Combination

## Key facts

- **NCT ID:** NCT04578106
- **Lead sponsor:** Fundacio Clinic Barcelona
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-09-23
- **Primary completion:** 2024-07-16
- **Final completion:** 2024-07-16
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** The study was prematurely halted primarily due to low patient accrual. Despite efforts to optimize recruitment, the enrollment rate remained insufficient to meet the predefined targets, and continuation was deemed unfeasible
- **Last updated:** 2026-01-06

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04578106

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04578106, "Omission of Surgery in Clinically Low-risk HER2positive Breast Cancer With High HER2 Addiction and a Complete Response Following Standard Anti-HER2-based Neoadjuvant Therapy". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04578106. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*